{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"253780","upperLimit":"770538","value":"533552"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Area under the plasma concentration-time curve to the last measurable time point (AUC0-t) calculated by the trapezoidal rule. The area under the concentration-time curve (AUC) is calculated to determine the total drug exposure over a period of time.","dispersionType":"Full Range","groups":[{"description":"Patients will receive 200 mg/m\\^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).\n\nMelphalan HCl for injection (propylene glycol free): During the study period, patients will receive 200 mg/m2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.","id":"OG000","title":"Melphalan HCl for Injection (Propylene Glycol Free)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Day -2","title":"AUC0-t (Pharmacokinetics)","type":"PRIMARY","unitOfMeasure":"ng*min/ml"}